The effect of nebivolol and atenolol on renal and systemic haemodynamics in hypertensive patients

High Blood Pressure and Cardiovascular Prevention

Volumn 14, Issue 3, 2007, Pages 133-137

  Van De Borne, Philippe ^a,d   Fici, Francesco ^b   Makel, Wim ^c   Fiasse, Annette ^a   Degaute, Jean Paul ^a   Leeman, Marc ^a  

^a ERASME HOSPITAL   (Belgium)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Clinical Research Facilities International   (Netherlands)

^d NONE   (Belgium)

Author keywords

Antihypertensive treatment; Atenolol; Glomerular filtration rate; Nebivolol; Renal blood flow

Indexed keywords

ATENOLOL; EDETIC ACID; IODOHIPPURIC ACID; N(G) METHYLARGININE; NEBIVOLOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; MALE; PARAMETER; PRIORITY JOURNAL; RADIAL BASED FUNCTION; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC CIRCULATION;

EID: 35248891603     PISSN: 11209879     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151642-200714030-00004     Document Type: Article

References (26)

1. Altwegg LA, d'Uscio LV, Barandier C, et al. Nebivolol induces NO-mediated relaxations of rat small mesenteric but not of large elastic arteries. J Cardiovasc Pharmacol 2000; 36: 316-20
2. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl 2004; 1: 2-16
3. Ladage D, Brixius K, Hoyer H, et al. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol 2006; 33: 720-4
4. Maffei A, Vecchione C, Aretini A, et al. Characterization of nitric oxide release by nebivolol and its metabolites. Am J Hypertens 2006; 19: 579-86
5. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-71
6. Dawes M, Brett SE, Chowienczyk PJ, et al. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999; 48: 460-3
7. Lekakis JP, Protogerou A, Papamichael C, et al. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs Ther 2005; 19: 277-81
8. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104: 511-4
9. Moen MD, Wagstaff AJ. Nebivolol: a review of its use in the management of hypertension and chronic heart failure. Drugs 2006; 66: 1389-409
10. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl 2004; 1: 17-32
11. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003; 92: 344-8
12. Brehm BR, Wolf SC, Gorner S, et al. Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study. Eur J Heart Fail 2002; 4: 757-63
13. Brune S, Schmidt T, Tebbe U, et al. Hemodynamic effects of nebivolol at rest and on exertion in patients with heart failure. Angiology 1990; 41: 696-701
14. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993; 21: 1094-100
15. Georgescu A, Pluteanu F, Flonta ML, et al. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol 2005; 508: 159-66
16. Greven J, Gabriels G. Effect of nebivolol, a novel beta 1-selective adrenoceptor antagonist with vasodilating properties, on kidney function. Arzneimittelforschung 2000; 50: 973-9
17. Kakoki M, Hirata Y, Hayakawa H, et al. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 1999; 33: 467-71
18. Dijkhorst-Oei LT, Rabelink TJ, Boer P, et al. Nifedipine attenuates systemic and renal vasoconstriction during nitric oxide inhibition in humans. Hypertension 1997; 29: 1192-8
19. Leeman M, Vereerstraeten P, Uytdenhoef M, et al. Systemic and renal hemodynamic responses to carvedilol and metoprolol in hypertensive renal transplant patients. J Cardiovasc Pharmacol 1993; 22: 706-10
20. Leeman M, van de BP, Collart F, et al. Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure. J Cardiovasc Pharmacol 1993; 22: 785-91
21. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112: 1198-205
22. Cupples WA, Braam B. Assessment of renal autoregulation. Am J Physiol Renal Physiol 2007; 292: F1105-23
23. Gosgnach W, Boixel C, Nevo N, et al. Nebivolol induces calcium-independent signalling in endothelial cells by a possible beta-adrenergic pathway. J Cardiovasc Pharmacol 2001; 38: 191-9
24. Parenti A, Filippi S, Amerini S, et al. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther 2000; 292: 698-703
25. Cowley Jr AW, Mori T, Mattson D, et al. Role of renal NO production in the regulation of medullary blood flow. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1355-9
26. Juncos LA, Garvin J, Carretero OA, et al. Flow modulates myogenic responses in isolated microperfused rabbit afferent arterioles via endothelium-derived nitric oxide. J Clin Invest 1995; 95: 2741-8